Amgen Inc. reported better-than-expected first-quarter results even as some newer drugs that analysts expect to drive growth over the next few years underperformed.

Amgen (NASDAQ:AMGN) executives said the company delivered a “strong first quarter” and remains positioned to meet its goals ...

By Deena Beasley April 30 (Reuters) - Amgen on Thursday said its first-quarter product sales rose 4%, helped by demand for ...

The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...

The biotechnology company reported a profit of $1.82 billion, driven by a 4% rise in product sales.

The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...

AMGN) on Thursday reported first-quarter profit of $1.82 billion. On a per-share basis, the Thousand Oaks, California-based company said it had profit of $3.34. Earnings, adjusted for non-recurring ...

Regeneron Pharmaceuticals Inc. asked a federal judge to require Amgen Inc. to turn over damages evidence for antitrust ...

The US Food and Drug Administration (FDA) is launching a pilot to implement real-time clinical trials (RTCT). While ...

Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the ...

The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with ...